DXCM: DexCom, Inc. - Summary | Jitta

DexCom, Inc.

NASDAQ:DXCM

Price
$108.43
Loss Chance
47.6%
5.40JITTA SCORE
190.24%Over Jitta Line
Jitta Ranking
84 / 1,189
1,242 / 4,967
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (54)
Recent Business Performance (28)
Financial Strength (73)
Return to Shareholders (39)
Competitive Advantage (73)
Jitta Signs
Revenue and EarningConsistent High Growth in the past 5 years
SG&A to SalesDecreasing
Operating MarginDeclined
Recent Business PerformanceEarning decline 24.55% in the last year
Key Stats
Jitta Score
Jitta Line
5.40
190.24%
2.00
228.54%
Health Care Equipment
6.94
124.04%
6.13
9.30%
5.92
580.60%
COMPANY DESCRIPTION
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company’s products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.